Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors cautious. See why ATYR stock is a Hold.

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company, is garnering attention from investors and analysts alike as it advances its lead candidate, efzofitimod, through late-stage ...

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1.

Researchers from Atyr Pharma Inc. presented preclinical efficacy data of ATYR-0101, a potential therapeutic biologic based on a domain appended to aspartyl-tRNA synthetase (DARS) in models of lung and ...

This very-high-yielding FTSE 100 heavyweight has fallen a long way since its 2017 peak, which has left it looking extremely undervalued, in my view. The post Investors considering a £9,000 investment ...

Roy covers the Healthcare sector, focusing on stocks such as Chimerix, aTyr Pharma, and Enliven Therapeutics. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in ...

JonesTrading analyst Soumit Roy has maintained their bullish stance on JANX stock, giving a Buy rating on December 27.Stay Ahead of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...